In another work, amniotic fluid MSCs were employed to investigate targeted ovarian cancer therapy, which required the usage of Lipofectamine 2000 to transfect MSCs with a plasmid that contained fluorescent IL-2. This evidence concerns the gene IL2 and ovarian carcinoma.